CN1114604C - 双环芳基甲酰胺及其治疗应用 - Google Patents

双环芳基甲酰胺及其治疗应用 Download PDF

Info

Publication number
CN1114604C
CN1114604C CN97199650A CN97199650A CN1114604C CN 1114604 C CN1114604 C CN 1114604C CN 97199650 A CN97199650 A CN 97199650A CN 97199650 A CN97199650 A CN 97199650A CN 1114604 C CN1114604 C CN 1114604C
Authority
CN
China
Prior art keywords
alkyl
compound
dichloropyridine
methoxyl group
methane amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97199650A
Other languages
English (en)
Chinese (zh)
Other versions
CN1237168A (zh
Inventor
H·J·戴克
J·G·蒙塔那
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9623860.5A external-priority patent/GB9623860D0/en
Priority claimed from GBGB9708062.6A external-priority patent/GB9708062D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of CN1237168A publication Critical patent/CN1237168A/zh
Application granted granted Critical
Publication of CN1114604C publication Critical patent/CN1114604C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN97199650A 1996-11-15 1997-11-17 双环芳基甲酰胺及其治疗应用 Expired - Fee Related CN1114604C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9623860.5A GB9623860D0 (en) 1996-11-15 1996-11-15 Novel compounds
GB9623860.5 1996-11-15
GBGB9708062.6A GB9708062D0 (en) 1997-04-22 1997-04-22 Novel compounds
GB9708062.6 1997-04-22

Publications (2)

Publication Number Publication Date
CN1237168A CN1237168A (zh) 1999-12-01
CN1114604C true CN1114604C (zh) 2003-07-16

Family

ID=26310411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97199650A Expired - Fee Related CN1114604C (zh) 1996-11-15 1997-11-17 双环芳基甲酰胺及其治疗应用

Country Status (22)

Country Link
US (2) US6353010B1 (enExample)
EP (1) EP0944616B1 (enExample)
JP (1) JP2001504479A (enExample)
KR (1) KR20000053274A (enExample)
CN (1) CN1114604C (enExample)
AT (1) ATE242234T1 (enExample)
AU (1) AU726590B2 (enExample)
BR (1) BR9713507A (enExample)
CA (1) CA2268037A1 (enExample)
CZ (1) CZ158299A3 (enExample)
DE (1) DE69722656T2 (enExample)
DK (1) DK0944616T3 (enExample)
ES (1) ES2200163T3 (enExample)
HU (1) HUP0000189A3 (enExample)
ID (1) ID21698A (enExample)
IL (1) IL129337A0 (enExample)
NO (1) NO992337D0 (enExample)
NZ (1) NZ335197A (enExample)
RU (1) RU2176642C2 (enExample)
SK (1) SK283534B6 (enExample)
TR (1) TR199901730T2 (enExample)
WO (1) WO1998022460A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440333A (zh) * 2018-03-29 2018-08-24 江苏道博化工有限公司 分散染料中间体的合成方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
WO2002102778A1 (en) * 2001-06-15 2002-12-27 Yamanouchi Pharmaceutical Co., Ltd. Phenylpyridine carbonyl piperazine derivative
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
CA2548172A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
JPWO2005087749A1 (ja) * 2004-03-15 2007-08-09 協和醗酵工業株式会社 ２−アミノキナゾリン誘導体
KR20070114748A (ko) * 2005-02-17 2007-12-04 에이엠알 테크놀로지, 인크. Ｃｉｎｖ 및 ｉｂｓ­ｄ를 치료하기 위한 벤족사졸카복스아미드
US7893267B2 (en) * 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
CA2642610A1 (en) * 2006-02-20 2007-08-30 Astellas Pharma Inc. Amide derivative or salt thereof
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2008019363A2 (en) * 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5ht3 modulators
JPWO2008026687A1 (ja) 2006-09-01 2010-01-21 杏林製薬株式会社 ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
EP2061786A2 (en) * 2006-09-07 2009-05-27 Biogen Idec MA Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
RU2529019C2 (ru) 2009-02-27 2014-09-27 Эмбит Байосайенсиз Корпорейшн Модулирующие jak киназу хиназолиновые производные и способы их применения
CA2810024A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
CN104428293B (zh) * 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
CN104780764A (zh) * 2012-09-05 2015-07-15 拜尔农作物科学股份公司 取代的2-酰氨基苯并咪唑、2-酰氨基苯并噁唑和2-酰氨基苯并噻唑或其盐作为活性物质对抗非生物植物胁迫的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011917A1 (en) * 1994-10-12 1996-04-25 Euro-Celtique, S.A. Novel benzoxazoles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140442A (enExample) 1974-04-16 1975-11-11
JPS59155357A (ja) 1983-02-14 1984-09-04 ユ−エスヴイ−・フア−マシユ−テイカル・コ−ポレ−シヨン ベンゾ複素環状カルバメイト
DE3835660A1 (de) * 1988-03-25 1989-10-12 Bayer Ag 7-substituierte 2-carbonamido-benzthiazol-3-oxide
DE4014937A1 (de) 1990-05-10 1991-11-14 Bayer Ag 2,3-disubstituierte chinoxaline als leistungsfoerderer fuer tiere
GB9219634D0 (en) 1992-09-16 1992-10-28 Ici Plc Heterocyclic compounds
GB9219632D0 (en) 1992-09-16 1992-10-28 Ici Plc Heterocyclic compounds
CA2144763A1 (en) 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
GB9301660D0 (en) 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
DE59508773D1 (de) * 1994-07-22 2000-11-09 Byk Gulden Lomberg Chem Fab Dihydrobenzofurane
US6083961A (en) 1994-08-03 2000-07-04 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole compounds as bradykinin antagonists
US5665737B1 (en) 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011917A1 (en) * 1994-10-12 1996-04-25 Euro-Celtique, S.A. Novel benzoxazoles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440333A (zh) * 2018-03-29 2018-08-24 江苏道博化工有限公司 分散染料中间体的合成方法

Also Published As

Publication number Publication date
NO992337L (no) 1999-05-14
AU4960297A (en) 1998-06-10
EP0944616A1 (en) 1999-09-29
DE69722656T2 (de) 2004-05-13
CA2268037A1 (en) 1998-05-28
US20020094987A1 (en) 2002-07-18
CN1237168A (zh) 1999-12-01
AU726590B2 (en) 2000-11-09
CZ158299A3 (cs) 1999-09-15
RU2176642C2 (ru) 2001-12-10
DK0944616T3 (da) 2003-09-29
ES2200163T3 (es) 2004-03-01
DE69722656D1 (de) 2003-07-10
SK64499A3 (en) 2000-03-13
NO992337D0 (no) 1999-05-14
ID21698A (id) 1999-07-15
EP0944616B1 (en) 2003-06-04
KR20000053274A (ko) 2000-08-25
WO1998022460A1 (en) 1998-05-28
ATE242234T1 (de) 2003-06-15
US6353010B1 (en) 2002-03-05
JP2001504479A (ja) 2001-04-03
NZ335197A (en) 2000-11-24
SK283534B6 (sk) 2003-09-11
TR199901730T2 (xx) 1999-09-21
HUP0000189A2 (hu) 2001-04-28
HUP0000189A3 (en) 2002-01-28
IL129337A0 (en) 2000-02-17
BR9713507A (pt) 2000-02-29

Similar Documents

Publication Publication Date Title
CN1114604C (zh) 双环芳基甲酰胺及其治疗应用
RU2170730C2 (ru) Хинолиновые карбоксамиды и фармацевтическая композиция на их основе
CN1219171A (zh) 苯并呋喃甲酰胺及其治疗用途
CN105120862A (zh) Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
CN1100773C (zh) 苯并呋喃羧酸胺和磺酰胺
US20100222368A1 (en) N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
AU2010314891A1 (en) Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US6313116B1 (en) Benzothiazole compounds and their therapeutic use
KR20220141331A (ko) P2x3 조정제
TW201343627A (zh) 作為蛋白質激酶抑制劑之吲哚啉－２－酮衍生物
KR101288698B1 (ko) Ｎ-(헤테로아릴)-１ｈ-인돌-2-카르복스아미드 유도체 및바닐로이드 ｔｒｐｖ１ 수용체 리간드로서의 그의 용도
CN1142227A (zh) 新的噻唑烷-4-酮衍生物
CA2719515C (en) A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
US6403791B1 (en) Heterocyclic compounds and their therapeutic use
CN87107723A (zh) 二氢吡啶抗变应性剂和抗炎性剂
WO2010057418A1 (zh) 苯氧基嘧啶衍生物及其制备方法和用途
CN1361773A (zh) 取代的3－吡啶基－4－芳基吡咯及治疗和预防相关疾病的方法
CN1290266A (zh) 苯并呋喃－4－甲酰胺和其治疗用途
WO2018042377A1 (en) Novel indazole compounds
CN1193029C (zh) 7－氨基吡啶并[2,3－d]嘧啶衍生物，其组合物及用途
KR101261006B1 (ko) Ｃ형 간염 바이러스의 활성을 억제하는 신규 5,6-디히드록시크로몬 유도체 및 그 제조방법
CN102076672A (zh) 新型五元环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1065821

Country of ref document: HK